93059-81-5Relevant academic research and scientific papers
PHARMACEUTICAL COMPOSITIONS CONTAINING POLY(ADP-RIBOSE) GLYCOHYDROLASE INHIBITORS AND METHODS OF USING THE SAME
-
, (2008/06/13)
The present invention relates to pharmaceutical compositions containing poly(ADP-ribose) glucohydrolase inhibitors, also known as PARG inhibitors, and methods of using the same for inhibiting or decreasing free radical induced cellular energy depletion, cell damage, or cell death. More particularly, the present invention relates to pharmaceutical compositions containing poly (ADP-ribose) glucohydrolase inhibitors such as glucose derivatives; lignin glycosides; hydrolysable tannins including gallotannins and ellagitannins; adenoside derivatives; acridine derivatives including 6,9-diamino-2-ethoxyacridine lactate monohydrate; tilorone analogs including tilorone R10.556, daunomycin or daunorubicin hydrochloride; ellipticine; proflavine; and other PARG inhibitors; and their method of use in treating or preventing diseases or conditions due to free radical induced cellular energy depletion and/or tissue damage resulting from cell damage or death due to necrosis, apoptosis, or combinations thereof.
On the basis for regioselective oxidation within a tetragalloylpyranose substrate
Feldman, Ken S.,Hunter, Kendra L.
, p. 8943 - 8946 (2007/10/03)
Lead (IV)-mediated oxidation of a benzyl 2,3,4,6- tetragalloylglucopyranoside leads only to coupling at the O(4)/O(6) galloyls. Competitive oxidation experiments with a series of positionally distinct phenolic galloyl analogs furnishes evidence that this unexpected regioselectivity stems from preferential oxidation at the O(6) galloyl ring. Companion studies with electronically dissimilar analogs provide support for a through-space component to O(6) galloyl oxidation selectivity in addition to steric and inductive influences.
Ellagitannin chemistry. The first total chemical synthesis of an ellagitannin natural product, tellimagrandin I
Feldman, Ken S.,Ensel, Susan M.,Minard, Robert D.
, p. 1742 - 1745 (2007/10/02)
Tellimagrandin I was synthesized by two different biogenetically patterned routes. One route featured diastereoselective galloyl ester coupling between the O(4) and O(6) galloyl moieties in a glucose-derived substrate bearing additional protected galloyl
